HALLE (SAALE) / Munich, Germany, 12 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced the postponement of the Annual General Meeting which was previously scheduled for June 24, 2020 in Halle (Saale). The decision was made by the Company’s management team with subsequent approval from the Supervisory Board.
The decision was made due to the ongoing SARS-CoV-2 global pandemic. According to the Fifth Ordinance on “Measures to Curb the Spread of the Novel Coronavirus SARS-CoV-2,” announced by the state government of Saxony-Anhalt on May 2, 2020, all events and gatherings with more than five people nationwide are prohibited until May 27, 2020.
Although the Annual General Meeting was scheduled to take place after the planned expiration date of the aforementioned ordinance, the invitation to the meeting would have had to be published before May 27, 2020. As it is unforeseeable whether the ordinance guidelines will be extended or changed, and in order to give shareholders appropriate planning time and to ensure their safety, the management team has decided to postpone the Annual General Meeting.
The Annual General Meeting is expected to be rescheduled for the second half of September 2020. The Company will inform its shareholders well in advance once a meeting date has been decided.
For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 176 2103 7191
Notes to Editors:
About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer’s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.